
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : GLB-COV2-043
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GLB-COV2-043 is a promising booster vaccine candidate component for adult participants who have received the 2-dose priming course of the mRNA BNT162b2 vaccine against COVID-19.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
February 01, 2023
Lead Product(s) : GLB-COV2-043
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Details : Under the collaboration, GreenLight Biosciences and Epivax Therapeutics will design and develop new personalized mRNA-based cancer vaccine candidates using GreenLight and EpiVax Therapeutics technology platforms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 09, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : GLB-COV2-043
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase I/II Study of GLB-COV2-043 as a COVID-19 Vaccine Booster
Details : GLB-COV2-043 is a Vaccine drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
November 02, 2022
Lead Product(s) : GLB-COV2-043
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : mRNA-Based COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : National Institutes of Health
Deal Size : Undisclosed
Deal Type : Collaboration
NIH, GreenLight Biosciences to Collaborate On COVID-19 Vaccine Development for New Variants
Details : GreenLight—in collaboration with the Vaccine Research Center, part of NIH’s National Institute of Allergy and Infectious Diseases—will co-design and test mRNA vaccines against coronaviruses with the goal of developing vaccines that confer a more du...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
July 29, 2022
Lead Product(s) : mRNA-Based COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : National Institutes of Health
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery Platform
Sponsor : Serum Institute of India
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Serum Institute of India and GreenLight Biosciences Multitarget Licensing Agreement
Details : Serum Institute of India has engaged GreenLight to design three messenger RNA products, including a vaccine for shingles. Serum Institute of India also has an option to expand the relationship further for two additional vaccine or therapeutic targets.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 14, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery Platform
Sponsor : Serum Institute of India
Deal Size : Undisclosed
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Flu Lab
Deal Size : $17.0 million
Deal Type : Financing
Details : This round of financing is aimed at establishing a scaled process under cGMP, capable of supporting clinical development and enabling the production of billions of doses of COVID-19 vaccine using GreenLight's proprietary bioprocessing technology.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
May 12, 2020
Lead Product(s) : mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Flu Lab
Deal Size : $17.0 million
Deal Type : Financing
